Clinical use of Insulin Degludec: Practical Experience and Pragmatic Suggestions

Sanjay Kalra, Yashdeep Gupta

Consultant (Endocrinology and Metabolism), Bharti Hospital, Karnal, Haryana, \(^1\)Department of Medicine, Government Medical College and Hospital, Chandigarh, India

Abstract

Insulin degludec (IDeg) is an ultralong acting basal insulin. IDeg has unique pharmacokinetic and pharmacodynamic properties which allow once a daily dosage, at any time of the day. Its use is associated with a significantly lower risk of hypoglycemia. This review discusses the pragmatic use of IDeg, based on available evidence. A complete search of all nine original research papers (BEGIN® clinical trial program) pertaining to IDeg, listed in PubMed, was made to prepare this article.

Keywords: Basal insulin, Insulin degludec, Diabetes, Insulin, Insulin analog, Person-centered care, Pragmatic use

Address of correspondence: Dr. Sanjay Kalra, DM Endocrinology, Consultant (Endocrinology and Metabolism), Bharti Hospital, Kunipura Road, Karnal - 132 001, Haryana, India. E-mail: brideknl@gmail.com

Introduction

Insulin degludec (IDeg) is an ultra long acting basal insulin which is available for use in many countries, including the European Union, India, Japan, Bangladesh, and Mexico. IDeg has unique pharmacokinetic and pharmacodynamic properties which allow once a daily dosage, at any time of the day. Its use is associated with a significantly lower risk of hypoglycemia, particularly nocturnal hypoglycemia and well-maintained quality of life. These advantages suggest that IDeg should be the basal insulin of choice, both as a basal regime and as part of a basal-bolus regime.

In out of pocket markets, where medications are not covered by insurance, the relative cost of IDeg does not allow it to be used for all patients requiring insulin. There is paucity of observational studies on IDeg so far, keeping its recent introduction into the market. The clinical use of IDeg is based upon the results from randomized controlled trials, as well as from clinical experience. This brief communication aims to clarify clinical situations in which IDeg can be of benefit, and collate collective personal experience of endocrinologists who manage diabetes on a day-to-day basis [Table 1]. A complete search of all the original research papers (BEGIN® clinical trial program) pertaining to IDeg, listed in PubMed (\(n = 9\)) was made to prepare this article.

Pharmacology of IDeg

IDeg is an ultra long acting insulin with a half-life of more than 24 h and a duration of action of more than 42 h.\(^3\) IDeg forms soluble and stable dihexamer in the pharmaceutical formulation with the help of phenol and zinc. After the injection, phenol diffuses away from the formulation leading to formation of a soluble depot in the form of long multihexamer chains experience slow diffusion of zinc from the end of their multihexamers causing a gradual, continuous, and extended release of monomers from the depot of injection site.\(^8\) This helps in achieving a steady state concentration, with a half-life of over 25 h, and duration of action of up to 42 h. Achievement of steady state concentration helps IDeg to have one-fourth glycemic variability as compared to insulin glargine (IGlar) at steady state concentration.\(^7\) This translates into a lower risk of hypoglycemia,
especially nocturnal hypoglycemia as seen in various clinical trials.[4,6]

The protein sequence of IDeg is based on human insulin, modified by acylating DesB30 at the e-amino group of LysB29 with hexadecandioic acid via a c-L-glutamic acid linker. IDeg (pH 7.4) is a clear, colorless solution with a pH-dependent solubility and an isoelectric point similar to that of human insulin, and it is administered subcutaneously.[8]

### Initiation Therapy with IDeg

IDeg has been extensively studied in the BEGIN® programme in a range of patients with type 1 or type 2 diabetes. The BEGIN® programme covered the spectrum of patients with diabetes who require insulin treatment (insulin-naive type 2 diabetes, insulin-treated type 2 and type 1 diabetes including basal-bolus therapy, basal plus oral therapy, and basal vs oral therapy, and also the flexible dosing options) [Table 1]. In a year-long trial that randomized 1,030 previously insulin-naive adult patients to once-daily degludec or glargine as addition to metformin ± dipeptidyl peptidase 4 (DPP-4) inhibitor, glycated hemoglobin (HbA1c) reduction was noninferior for degludec, while the fasting plasma glucose (FPG) reduction was significantly greater using similar insulin doses.[11] Though overall hypoglycemia rates were low and similar for degludec and glargine, nocturnal hypoglycemia occurred at a significantly lower rate (36%) with degludec. Severe hypoglycemias occurred rarely and at significantly (86%) lower frequency with degludec. Similar results were seen in other trials of 26 weeks duration and, in which number of insulin naïve subjects were less in number.[1,5,9,10] The dose titration algorithm followed in the BEGIN studies are presented in Table 2.

### Switch Therapy to IDeg

Randomized controlled trials have been conducted, in which IDeg has been used to replace other basal insulins such as IGlar or neutral protamine Hagedorn (NPH). Participants receiving once-daily basal insulin prior to the study were switched to IGlar or IDeg on a unit for unit dose basis; whereas, those on a twice-daily basal insulin regimen were switched to lower (20-30%) starting doses of IGlar. At the end, doses were similar in all arms.[10,11] In terms of HbA1c reduction, IDeg was noninferior to IGlar. In addition, there was no significant between-group difference in the proportion of patients achieving an HbA1c of <7%. The rate of nocturnal hypoglycemia was significantly 25% lower with degludec than glargine,[1,2] while rates of overall hypoglycemia were similar.[10-12] In another study, rates of overall and nocturnal hypoglycemia were significantly lower with degludec than glargine, being reduced by 18 and 25%, respectively.[13] The difference in nocturnal hypoglycemia rates became more evident after about 16-20 weeks, perhaps indicating that this difference is more likely to manifest after initial titration when patients have reached stable doses of basal insulin.[11]

### Practical Experience, Pragmatic Suggestions

**Insulin initiation**

IDeg can be used as basal insulin, or as part of a basal-bolus or basal-plus regime in persons with type-2 diabetes. It can also be used to initiate basal-bolus therapy in newly diagnosed type1 diabetes patients. It must be noted that IDeg is currently not approved for use in children below the age of 18, and in pregnancy.

---

**Table 1: Clinical trial program of IDeg (BEGIN)**

| Clinical trial | Study population | Efficacy: Reduction in HbA1c with IDeg vs IGlar, ETD (%) | Dose of IDeg (first week of trial) U/Kg | Dose of IDeg (end of trial) U/Kg | Dose of insulin glargine (1st week of trial) U/Kg | Dose of insulin glargine (end of trial) U/Kg |
|----------------|------------------|--------------------------------------------------------|----------------------------------------|----------------------------------|-----------------------------------------------|---------------------------------------------|
| BEGIN_: T1[1]  | T1DM             | -0.01; noninferior                                     | 0.35                                   | 0.35                             | 0.33                                          | 0.39                                        |
| BEGIN_: Flex T1[2] | T1DM             | 0.17; noninferior                                      | 0.35                                   | 0.40                             | 0.35                                          | 0.42                                        |
| BEGIN_: Once Long[3] | T2DM, insulin naive | 0.09; noninferior                                      | 0.12                                   | 0.11                             | 0.59                                          | 0.60                                        |
| BEGIN_: Low Volume[4] | T2DM, insulin naive | 0.04; noninferior                                      | 10 U (not based on U/Kg)             | 0.53                             | 10 U (not based on U/Kg)                      | 0.60                                        |
| BEGIN_: BB[5]   | T2DM             | 0.08; noninferior                                      | 0.45                                   | 0.75                             | 0.44                                          | 0.69                                        |
| BEGIN_: Flex[6] | T2DM, insulin naive and insulin treated | 0.04; noninferior                                      | Not mentioned                          | Not mentioned                    | Not mentioned                               | Not mentioned                              |
| BEGIN_: Once Asia[7] | T2DM, insulin naive | 0.11; noninferior                                      | 0.14                                   | 0.28                             | 0.14                                          | 0.35                                        |

IDeg = Insulin degludec, HbA1c = Glycated hemoglobin, IGlar = Insulin glargine, T1DM = Type 1 diabetes mellitus, T2DM = Type 2 diabetes mellitus, ETD = Estimated treatment difference
The indications for use of IDeg as initial basal therapy do not differ from those for other basal insulins [Table 3]. There is fair acceptance of this molecule by patients, though some verbalize their concern about cost. The ability to inject IDeg at any time of the day is a major driver for acceptance of this drug, in spite of its cost. The characteristic of ultra long acting IDeg appeals to busy persons with erratic lifestyle routines, and to persons who are dependent upon others for injections, for example, elderly persons with limited manual dexterity or cognitive function, nursing home residents, and indoor patients. However, the ability to inject IDeg more flexibly should not detract from the message that it should be injected at the same time each day.[10,11] IDeg finds excellent acceptance as part of initial basal-bolus therapy, in patients with severe, acute comorbid conditions requiring immediate control. These include life-threatening conditions such as diabetic ketoacidosis (DKA), organ threatening complications like vitreous hemorrhage or chronic renal failure,[14] and limb-threatening illness such as complicated diabetic foot ulcer. Major infections, for example, tuberculosis, lung abscess, skin and soft tissue infections, and preoperative patients requiring glycemic control, are also indications where the pharmacodynamic properties of IDeg can be utilized as part of a basal-bolus regime [Table 3].

### Switch therapy
IDeg can be used in persons not responding to other basal insulins.[14] The concept of basal insulin failure as a single homogenous entity has been challenged by recent developments in pharmacotherapeutics. The

### Table 2: BEGIN Once Simple titration algorithms[^8]

| Pre-breakfast SMBG | Dose adjustment IDEG simple | Dose adjustment IDEG step-wise |
|---------------------|-----------------------------|-------------------------------|
| mmol/L mg/dL        |                             |                               |
| <3.1 <56            | U                           | U                             |
| 3.1-3.9 56-70       | -4                          | -4                            |
| 4.0-5.0 71-90       | 0                           | 0                             |
| 5.1-7.0 91-126      | +4                          | +2                            |
| 7.1-8.0 127-144     | +4                          |                               |
| 8.1-9.0 145-162     | +6                          |                               |
| >9.0 >162           | +8                          |                               |

IDeg = Insulin degludec, SMBG = self-measured blood glucose. *Based on a single measurement on the day of titration, bBased on the lowest of 3 consecutive days’ measurements

### Table 3: Insulin degludec: Pragmatic usage patterns

| Regime                        | Prior therapy                        | Justification                                      | Remarks                                      |
|-------------------------------|--------------------------------------|----------------------------------------------------|----------------------------------------------|
| Initiation therapy            | As basal insulin                      | Poor control, especially high fasting glucose      | Fair acceptance                             |
|                               | Dual/triple/quadruple OHA therapy    |                                                    | Concern about cost                           |
|                               | Severe, acute comorbid condition     | Good acceptance in life-threatening (DKA)          | Ability to inject at any time of day is      |
|                               | requiring intensive glycemic control | limb-threatening (diabetes foot), sight-threatening (vitreous hemorrhage), organ-threatening (lung) conditions | a major driver                                |
|                               | Poor control in spite of adequate    | Good acceptance if patient is dependent a family   |
|                               | dosage. Excessive variability        | member or health care professional to inject       |
|                               | of control, e.g., Somogyi phenomenon | insulin at specific time of day/on two basal       |
|                               | and Dawn phenomenon                  | injection                                           |
|                               | Poor fasting control                 | Patients accept finite trial of degludec to assess impact on variability and control |
|                               | Overall poor control in spite of     | Reduction in hypoglycemic episodes                 | Same as above                                |
|                               | highdoses. Variability; frequent hypoglycemia | | |
|                               | from premixed insulin once daily     | Good acceptance if existing doses are higher/two basal injection used | Good acceptance if existing doses are higher/two basal injection used |
|                               | Biphasic insulin od                  | Patients welcome the freedom to adjust timing of injections | Patients welcome the freedom to adjust timing of injections |
|                               | 3 prandial + 1 or 2 basal insulin   | Cost containment: Regular insulin tds + degludec od | |

OHA = Oral hypoglycemic agent, NPH = Neutral protamine hagedorn, DKA = Diabetic ketoacidosis

[^8]: North American Journal of Medical Sciences | Mar 2015 | Volume 7 | Issue 3 | 83
improved pharmacokinetic and pharmacodynamic properties of basal insulin analogs facilitate better glycemic control. This means that a person who is labeled as having basal insulin failure, because of lack of response to a particular molecule, may respond to different basal insulin. For example, a person on NPH insulin or glargine who is unable to achieve glycemic targets without experiencing significant hypoglycemia may respond to IDeg.[10-14]

This advantage of IDeg holds true in both basal and basal-bolus regimes. While there is a concern about cost, most patients accept a finite trial of IDeg to experience its efficacy, tolerability, and safety. Patients who are unable to achieve glycemic control inspite of high doses of once daily or twice daily conventional basal insulin accept IDeg easily. Patients who experience variability with conventional insulin, for example, Somogyi phenomenon, or report poor control, for example, Dawn phenomenon, are also candidates for IDeg. The peakless, long duration of action of IDeg helps improve glycemic control in such persons. This benefit is experienced in both type 1 and type 2 patients.

Some patients on basal-bolus regime using NPH insulin or glargine, in fact, may be able to shift to basal-plus regimes with IDeg. This is perceived as a major advantage by persons who find it difficult to adhere to a lunch time injection of insulin.

At times, persons on once daily premixed insulin, who request flexibility in injection times, or who experience hypoglycemia, may benefit from a switch to once daily IDeg. Such a switch, however, should be made carefully, under close medical supervision.

Dosage
Most randomized controlled trials on degludec report a similar dose requirement of degludec, as compared to other basal analogs. Some trials, however, find a slightly lesser dose requirement of degludec (14-20%) [Table 1].[5,12]

In practice, however, we find that a 20-30% lesser dose is required for this drug, as compared to other basal insulins. This is reflected in recommendations to consider a dose reduction of 20-30% if a twice daily basal regime is converted to once daily analog.[14,15] This feature encourages switch from other basal insulins to IDeg.

Adherence to therapy
Lack of adherence to insulin therapy is a significant contributor to the lack of improvement in average HbA1c levels across the world. The flexibility of taking IDeg at any time of the day, with an acceptable interinjection period of 8-42 h provides welcome convenience to the person with diabetes which comes with efficacy along with a much lower risk of hypoglycemia. This in turn instills a sense of confidence in the user as well as her or his family, and reduces the fears related to hypoglycemia.[11]

Conclusion
This brief communication describes collated experiences of endocrinologists in the use of IDeg. It supplements the knowledge gained from preclinical trials and clinical randomized controlled trials, with understanding gleaned from extensive clinical experience. This information will be of benefit to other diabetes care professionals who wish to use IDeg in their clinical practice.

References
1. Philis-Tsimikas A, Del Prato S, Satman I, Bhargava A, Dharmalingam M, Skjøth TV, et al. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab 2013;15:760-6.
2. Zinman B, Philis-Tsimikas A, Cariou B, Handselms Y, Rodbard HW, Johansen T, et al. NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35:2464-71.
3. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14:944-50.
4. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, et al. Insulin degludec in type 1 diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011;34:661-5.
5. Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig 2013;4:605-12.
6. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, et al. NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with metformine insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3 randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1498-507.
7. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H, et al. Insulin degludec: Four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-64.
8. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, ultra-long-acting basal insulin. Pharm Res 2012;29:2104-14.
9. Gough S, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low volume insulin degludec 200 U/ml once-daily improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN™ LOW VOLUME trial. Diabetes Care 2013;36:2536-42.

10. Meneghini L, Atkin S, Gough S, Raz I, Blonde L, Shestakova M, et al. NN1250-3668 (BEGIN FLEX) Trial Investigators, on behalf of the NN1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013;36:858-64.

11. Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, et al. NN1250-3770 (BEGIN: Flex T1) Trial Investigators. Efficacy and safety of insulin degludec in a flexible dosing regimen versus insulin glargine in patients with type 1 diabetes (BEGIN®: Flex T1): A 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013;98:1154-62.

12. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): A phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1489-97.

13. Sinha B, Gangopadhyay KK, Ghosal S. Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India. Diabetes Metab Syndr Obes 2014;7:225-8.

14. Kalra S. Newer basal insulin analogues: Degludec, detemir, glargine. J Pak Med Assoc 2013;63:1442-4.

15. Kalra S, Unnikrishnan AG, Das AK. Improving adherence to insulin: Hope with degludec. J Soc Health Diabetes 2014;2:1-2.

How to cite this article: Kalra S, Gupta Y. Clinical use of insulin degludec: Practical experience and pragmatic suggestions. North Am J Med Sci 2015;7:81-5.

Source of Support: Nil. Conflict of Interest: None declared.